4.5 Article

Body Surface Area: A New Predictor Factor for Conversion and Prolonged Operative Time in Laparoscopic Colorectal Surgery

Journal

DISEASES OF THE COLON & RECTUM
Volume 55, Issue 11, Pages 1153-1159

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/DCR.0b013e3182686230

Keywords

Laparoscopic colorectal surgery; Body surface area; Conversion; Short-term outcomes; Operative time; Operative difficulties

Ask authors/readers for more resources

BACKGROUND: Body surface area is a measurement of body size used in clinical settings. Its impact on laparoscopic colorectal surgery has not been previously studied. OBJECTIVE: The aim of this study was to assess the impact of body surface area on the conversion rate and laparoscopic operative time. DESIGN: This study was conducted as a retrospective analysis of prospectively collected data SETTING: This study was conducted at a single tertiary care institution. PATIENTS: Nine hundred sixteen consecutive patients operated on between January 2004 and August 2011 were identified from a prospective database. MAIN OUTCOME MEASURES: Conversion rate and laparoscopic operative time were analyzed related to age, sex, obesity, disease location (colon vs rectum), type of disease (neoplastic vs nonneoplastic), history of previous surgery, and body surface area; body surface area was calculated by the Mosteller formula. Body surface area was analyzed by the use of median and quartile cutoff values (1.6, 1.8, and 2.0). Multivariate models were adjusted for different confounders. Interaction between body surface area and BMI was ruled out. RESULTS: The conversion rate was 10%. Conversion rates for quartiles 1, 2, 3, and 4 were 4.4%, 8.3%, 12.7%, and 14.8%, p = 0.001. Patients with body surface area >= 1.8 had a higher conversion rate than those with body surface area <1.8 (13.9% vs 5.3%, OR: 2.35 (95% CI: 1.45-3.86; p = 0.0001)). Multivariate analysis showed that body surface area >= 1.8 was associated with conversion (OR: 2, 95% CI: 1.1-3.7, p = 0.02) and a longer operative time after adjusting for sex, age, obesity, disease location (rectum vs colon), and type of laparoscopic approach. LIMITATION: This was a single-institution retrospective study. CONCLUSION: Body surface area is a predictor for conversion and longer laparoscopic operative time. It should be considered when informing patients, selecting cases in the early learning curve, and assessing standard of care.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Fluoroscopy and endoscopy-guided transanastomotic rendezvous: a novel technique for recanalization of a completely obstructed colorectal anastomosis

Agustina Bequis, Marcos Gonzalez, Julian Fernandez Aramburu, Pablo Huespe, Sebastian Duran, Sung Ho Hyon, Carlos A. Vaccaro

Summary: Endoscopic balloon dilation is the preferred therapy with surgical revision as an alternative; a modified rendezvous technique can effectively treat complete colorectal anastomotic stricture.

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2021)

Article Rheumatology

Effect of Tocilizumab on LDL and HDL Characteristics in Patients with Rheumatoid Arthritis. An Observational Study

Florencia S. Pierini, Eliana Botta, Enrique R. Soriano, Maximiliano Martin, Laura Boero, Tomas Merono, Maria Soledad Saez, Ezequiel Lozano Chiappe, Osvaldo Cerda, Gustavo Citera, Ignacio Gandino, Javier Rosa, Patricia Sorroche, Anatol Kontush, Fernando Brites

Summary: Treatment with tocilizumab can reduce inflammation levels and improve lipid profiles in patients with rheumatoid arthritis, specifically lowering levels of LDL and Lp(a), while not affecting the ability of HDL to promote cellular cholesterol efflux.

RHEUMATOLOGY AND THERAPY (2021)

Article Rheumatology

Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis

Maria Laura Acosta Felquer, Luciano LoGiudice, Maria Laura Galimberti, Javier Rosa, Luis Mazzuoccolo, Enrique R. Soriano

Summary: The study found that using biologics in patients with psoriasis can reduce the risk of developing psoriatic arthritis (PsA).

ANNALS OF THE RHEUMATIC DISEASES (2022)

Letter Rheumatology

Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Braun and Landewe

Dafna D. Gladman, Philip J. Mease, Paul Bird, Enrique R. Soriano, Soumya D. Chakravarty, May Shawi, Frederic Lavie, Cinty Gong, Evan Leibowitz, Denis Poddubnyy, Lai-Shan Tam, Philip S. Helliwell, Arthur Kavanaugh, Atul A. Deodhar, Mikkel Ostergaard, Xenofon Baraliakos

ANNALS OF THE RHEUMATIC DISEASES (2023)

Editorial Material Rheumatology

Prologue: Evidence Informing the GRAPPA 2021 Treatment Recommendations, by Domain

Enrique R. Soriano, Arthur Kavanaugh, Laura C. Coates

JOURNAL OF RHEUMATOLOGY (2023)

Article Rheumatology

Incidence and Prevalence of Polymyalgia Rheumatica and Giant Cell Arteritis in a Healthcare Management Organization in Buenos Aires, Argentina

Jose Maximiliano Martinez Perez, Florencia Beatriz Mollerach, Valeria Scaglioni, Facundo Vergara, Ignacio Javier Gandino, Luis Jose Catoggio, Javier Eduardo Rosa, Enrique Roberto Soriano, Marina Scolnik

Summary: This study estimated the incidence and prevalence of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in Argentina. The results showed a relatively higher incidence and prevalence of PMR, while the incidence and prevalence of GCA were lower.

JOURNAL OF RHEUMATOLOGY (2023)

Article Medicine, Research & Experimental

Efficacy and safety of guselkumab in biologic-naive patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial

Dafna D. Gladman, Philip J. Mease, Paul Bird, Enrique R. Soriano, Soumya D. Chakravarty, May Shawi, Stephen Xu, Sean T. Quinn, Cinty Gong, Evan Leibowitz, Denis Poddubnyy, Lai-Shan Tam, Philip S. Helliwell, Arthur Kavanaugh, Atul Deodhar, Mikkel Ostergaard, Xenofon Baraliakos

Summary: This study aims to evaluate the efficacy of guselkumab in reducing axial symptoms and inflammation in patients with active PsA.

TRIALS (2022)

Review Rheumatology

Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients with Psoriatic Arthritis: An Updated Review the 2021 GRAPPA Treatment Recommendations

Deepak R. Jadon, Nadia Corp, Danielle A. van der Windt, Laura C. Coates, Enrique R. Soriano, Arthur Kavanaugh, Tim Raine, Florian Rieder, Stefan Siebert, Michel Zummer, Sergio Schwartzman, James T. Rosenbaum, Brigitte Michelsen, Ramasharan Laxminarayan, Dongze Wu, Latika Gupta, Beverly Ng, Hannah Jethwa, Nick De Windt, Tania Gudu, Joseph Hutton, Denis O'Sullivan, Michele M. Luchetti, Matthew Stoll, Jasvinder A. Singh, Rosario Peluso, Judith Rademacher, M. Elaine Husni

Summary: This study summarizes the efficacy and safety of advanced therapies for psoriatic arthritis in patients with related conditions, including Crohn's disease, ulcerative colitis, and noninfectious uveitis. The tumor necrosis factor inhibitor (TNFi) class appears to be effective and safe, while interleukin 12/23 inhibitors (IL-12/23i) show efficacy in Crohn's disease and ulcerative colitis. However, caution should be exercised when using interleukin 17 inhibitors (IL-17i) in patients with psoriatic arthritis at high risk of inflammatory bowel disease.

JOURNAL OF RHEUMATOLOGY (2023)

Article Rheumatology

Towards healthy populations: A need to strengthen systems for musculoskeletal health

Andrew M. Briggs, Neil Betteridge, Karsten E. Dreinhoefer, Syed Atiqul Haq, Carmen Huckel Schneider, Asgar Ali Kalla, Deborah Kopansky-Giles, Lyn March, Saurab Sharma, Enrique R. Soriano, Anthony D. Woolf, James J. Young, Helen Slater

SEMINARS IN ARTHRITIS AND RHEUMATISM (2023)

Article Rheumatology

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study

Christopher T. Ritchlin, Atul Deodhar, Wolf-Henning Boehncke, Enrique R. Soriano, Alexa P. Kollmeier, Xie L. Xu, Federico Zazzetti, May Shawi, Yusang Jiang, Shihong Sheng, Philip S. Helliwell

Summary: This study evaluated the efficacy and safety of guselkumab, an interleukin-23p19-subunit inhibitor, in patients with active psoriatic arthritis (PsA) who had previously used a tumor necrosis factor inhibitor (TNFi). The results showed that guselkumab provided sustained improvements across multiple domains in both TNFi-naive and TNFi-experienced patients with active PsA, and TNFi-naive patients were more likely to achieve treatment goals related to physical function and pain.

ACR OPEN RHEUMATOLOGY (2023)

Editorial Material Rheumatology

25 years of biologic DMARDs in rheumatology

Marc Feldmann, Ravinder N. Maini, Enrique R. Soriano, Vibeke Strand, Tsutomu Takeuchi

Summary: In this Viewpoint article, five rheumatology researchers discuss how biologic therapy has transformed clinical practice and reflect on their own experiences, past and current challenges, and the future prospects of biologic drugs.

NATURE REVIEWS RHEUMATOLOGY (2023)

Article Gastroenterology & Hepatology

Long-term outcomes and risk factors for diverticulitis recurrence after a successful laparoscopic peritoneal lavage in Hinchey III peritonitis

Juan P. Campana, Ricardo E. Mentz, Esteban Gonzlez Salazar, Marcos Gonzalez, Gabriel Moya Rocabado, Carlos A. Vaccaro, Gustavo L. Rossi

Summary: The study aimed to determine the recurrence rate of diverticulitis after a successful laparoscopic peritoneal lavage in Hinchey III diverticulitis, and to identify associated risk factors and elective sigmoidectomy rate. The study found that the recurrence rate of diverticulitis after laparoscopic peritoneal lavage is high, and smoking and previous acute diverticulitis episodes independently increase the risk of new episodes.

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2023)

Article Rheumatology

Prognostic factors associated with advanced chronic kidney disease in a cohort of patients with ANCA vasculitis and renal involvement

Gelsomina Alle, Marina Scolnik, Valeria Scaglioni, John F. Jaramillo Gallego, Carlos. F. F. Varela, Gustavo Greloni, Javier Rosa, Enrique. R. R. Soriano

Summary: The aim of this study was to evaluate prognostic factors associated with advanced chronic kidney disease (ACKD) in patients with ANCA-associated vasculitis and renal involvement. A retrospective observational study was conducted to collect clinical-analytical data, renal histopathology, and treatment information of patients diagnosed with ANCA glomerulonephritis between 2001 and 2016. The results suggested that creatinine at diagnosis and eGFR after 6 and 12 months of treatment were the best predictors of ACKD at the end of follow-up.

RHEUMATOLOGY INTERNATIONAL (2023)

Article Rheumatology

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naive or TNFα inhibitor-experienced

Christopher T. Ritchlin, Philip S. Helliwell, Wolf-Henning Boehncke, Enrique R. Soriano, Elizabeth C. Hsia, Alexa P. Kollmeier, Soumya D. Chakravarty, Federico Zazzetti, Ramanand A. Subramanian, Xie L. Xu, Qing C. Zuraw, Shihong Sheng, Yusang Jiang, Prasheen Agarwal, Bei Zhou, Yanli Zhuang, May Shawi, Chetan S. Karyekar, Atul Deodhar

Summary: The study demonstrated that guselkumab provided sustained improvement in patients with Psoriatic Arthritis, maintaining a favorable benefit-risk profile regardless of prior TNFi exposure.

RMD OPEN (2021)

No Data Available